Episode

E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA

Podcast: The Evidence Based Rheumatology Podcast
Published: Apr 30, 2025
Duration seconds: 1093
Processing state: not_requested
Canonical source: https://msputman.podbean.com/e/e123-upadacitinib-for-giant-cell-arteritis-select-gca/
Audio: https://mcdn.podbean.com/mf/web/fjeegi8sd278rqhk/e123.mp3
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e123-upadacitinib-for-giant-cell-arteritis-select-gca
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175/e123-upadacitinib-for-giant-cell-arteritis-select-gca.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e123-upadacitinib-for-giant-cell-arteritis-select-gca/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e123-upadacitinib-for-giant-cell-arteritis-select-gca.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449